Page 4 - Lymphoma Program News Today

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate

Glofitamab is the first bispecific antibody with a fixed-duration treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

A PD-1 checkpoint inhibitor plus chemotherapy is expected to become new standard of care for advanced lymphoma, based on Phase III trial data.

Miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

Fred Hutchinson Cancer Center is one of few centers in the United States that has experience treating cutaneous lymphoma and specializes in providing novel therapies and clinical studies for this rare disease.

Data Will Also Be Presented in a Poster Session at the American Society of Clinical Oncology Annual Meeting on June 3, 2023 SOUTH SAN FRANCISCO, Calif., May 11, 2023 -- Allogene Therapeutics,... | May 11, 2023

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.

TUESDAY, Dec. 27, 2022 (HealthDay News) -- Young adults with cancer, especially those who are Hispanic or Black, had better outcomes because of coverage available to them under the Affordable